

Miriam Martini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4436853/publications.pdf>

Version: 2024-02-01

43
papers

6,920
citations

236925

25
h-index

276875

41
g-index

44
all docs

44
docs citations

44
times ranked

10419
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. <i>Lancet Oncology</i> , The, 2010, 11, 753-762.	10.7	1,915
2	Wild-Type <i>BRAF</i> Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 5705-5712.	1.6	1,540
3	PI3K/AKT signaling pathway and cancer: an updated review. <i>Annals of Medicine</i> , 2014, 46, 372-383.	3.8	887
4	<i>PIK3CA</i> Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies. <i>Cancer Research</i> , 2009, 69, 1851-1857.	0.9	711
5	Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer. <i>PLoS ONE</i> , 2009, 4, e7287.	2.5	241
6	PI3K Class II $\hat{1}\pm$ Controls Spatially Restricted Endosomal PtdIns3P and Rab11 Activation to Promote Primary Cilium Function. <i>Developmental Cell</i> , 2014, 28, 647-658.	7.0	177
7	Measurement of PIP3 Levels Reveals an Unexpected Role for p110 $\hat{1}\pm$ in Early Adaptive Responses to p110 $\hat{1}\pm$ -Specific Inhibitors in Luminal Breast Cancer. <i>Cancer Cell</i> , 2015, 27, 97-108.	16.8	165
8	Phosphoinositide 3-Kinase Gamma Inhibition Protects From Anthracycline Cardiotoxicity and Reduces Tumor Growth. <i>Circulation</i> , 2018, 138, 696-711.	1.6	145
9	Class II PI3K Functions in Cell Biology and Disease. <i>Trends in Cell Biology</i> , 2019, 29, 339-359.	7.9	99
10	Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 20864-20869.	7.1	95
11	Targeted therapies: how personal should we go?. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 87-97.	27.6	94
12	Targeting PI3K in Cancer: Any Good News?. <i>Frontiers in Oncology</i> , 2013, 3, 108.	2.8	87
13	Mitotic Spindle Assembly and Genomic Stability in Breast Cancer Require PI3K-C2 $\hat{1}\pm$ Scaffolding Function. <i>Cancer Cell</i> , 2017, 32, 444-459.e7.	16.8	69
14	Signaling Pathways Regulating Redox Balance in Cancer Metabolism. <i>Frontiers in Oncology</i> , 2018, 8, 126.	2.8	57
15	PI3K in cancer $\hat{1}\pm$ stroma interactions: bad in seed and ugly in soil. <i>Oncogene</i> , 2014, 33, 3083-3090.	5.9	55
16	Targeting PI3K signaling in cancer: Challenges and advances. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2019, 1871, 361-366.	7.4	54
17	Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, E353-9.	7.1	51
18	PI(3,4)P2 Signaling in Cancer and Metabolism. <i>Frontiers in Oncology</i> , 2020, 10, 360.	2.8	48

#	ARTICLE	IF	CITATIONS
19	PI3K keeps the balance between metabolism and cancer. <i>Advances in Biological Regulation</i> , 2012, 52, 389-405.	2.3	37
20	A Novel Multiplex qRT-PCR Assay to Detect SARS-CoV-2 Infection: High Sensitivity and Increased Testing Capacity. <i>Microorganisms</i> , 2020, 8, 1064.	3.6	37
21	PI(3,4)P2-mediated cytokinetic abscission prevents early senescence and cataract formation. <i>Science</i> , 2021, 374, eabk0410.	12.6	37
22	Prospects of targeting PI3K/AKT/mTOR pathway in pancreatic cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 176, 103749.	4.4	37
23	Knock-in of Oncogenic <i>Kras</i> Does Not Transform Mouse Somatic Cells But Triggers a Transcriptional Response that Classifies Human Cancers. <i>Cancer Research</i> , 2007, 67, 8468-8476.	0.9	32
24	PI3K Signaling in Tissue Hyper-Proliferation: From Overgrowth Syndromes to Kidney Cysts. <i>Cancers</i> , 2017, 9, 30.	3.7	29
25	Integrated molecular dissection of the epidermal growth factor receptor (EGFR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer. <i>Targeted Oncology</i> , 2010, 5, 19-28.	3.6	27
26	Iron supplementation is sufficient to rescue skeletal muscle mass and function in cancer cachexia. <i>EMBO Reports</i> , 2022, 23, e53746.	4.5	26
27	The role of metabolic adaptation to nutrient stress in pancreatic cancer. <i>Cell Stress</i> , 2018, 2, 332-339.	3.2	19
28	<i>BRAF</i> V600E Is a Determinant of Sensitivity to Proteasome Inhibitors. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 2950-2961.	4.1	18
29	Mixed Lineage Kinase MLK4 Is Activated in Colorectal Cancers Where It Synergistically Cooperates with Activated RAS Signaling in Driving Tumorigenesis. <i>Cancer Research</i> , 2013, 73, 1912-1921.	0.9	15
30	Cytokinetic Abscission: Phosphoinositides and ESCRT Direct the Final Cut. <i>Journal of Cellular Biochemistry</i> , 2017, 118, 3561-3568.	2.6	15
31	Rac signal adaptation controls neutrophil mobilization from the bone marrow. <i>Science Signaling</i> , 2016, 9, ra124.	3.6	14
32	Phosphoinositides in cell proliferation and metabolism. <i>Advances in Biological Regulation</i> , 2020, 75, 100693.	2.3	14
33	How PI3K-derived lipids control cell division. <i>Frontiers in Cell and Developmental Biology</i> , 2015, 3, 61.	3.7	13
34	Protective Role of the M-Sec Tunneling Nanotube System in Podocytes. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 1114-1130.	6.1	12
35	Defective lipid signalling caused by mutations in <i>PIK3C2B</i> underlies focal epilepsy. <i>Brain</i> , 2022, 145, 2313-2331.	7.6	10
36	The impact of COVID-19 on pancreatic cancer research and the path forward. <i>Gastroenterology</i> , 2021, 161, 1758-1763.	1.3	8

#	ARTICLE	IF	CITATIONS
37	Phosphoinositide Conversion Inactivates RAS and Drives Metastases in Breast Cancer. <i>Advanced Science</i> , 2022, 9, e2103249.	11.2	8
38	Lysosomal lipid switch sensitises to nutrient deprivation and mTOR targeting in pancreatic cancer. <i>Gut</i> , 2023, 72, 360-371.	12.1	8
39	Modeling Tumor Progression by the Sequential Introduction of Genetic Alterations into the Genome of Human Normal Cells. <i>Human Mutation</i> , 2013, 34, 330-337.	2.5	6
40	Cholesterol Activates Cyclic AMP Signaling in Metaplastic Acinar Cells. <i>Metabolites</i> , 2021, 11, 141.	2.9	4
41	Docking Protein p130Cas Regulates Acinar to Ductal Metaplasia During Pancreatic Adenocarcinoma Development and Pancreatitis. <i>Gastroenterology</i> , 2022, 162, 1242-1255.e11.	1.3	4
42	The turtle and the rabbit story in a modern (PI3)key. <i>Molecular and Cellular Oncology</i> , 2018, 5, e1405141.	0.7	0
43	Abstract B229: Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. , 2009, , .		0